Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.39 |
| ▸ | ATR | Q13535 | 5/20 | 0.38 |
| ▸ | KRAS | P01116 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 6/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30860903 | 0.89 | RXRA (0.42) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL31105951 | 0.87 | LCK (0.43) | ATRLCK | |
| SCHEMBL27227895 | 0.86 | RXRA (0.47) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL30860896 | 0.82 | CYP4F2 (0.39) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL25787278 | 0.81 | CYP4F2 (0.43) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL29135801 | 0.79 | RXRA (0.52) | RXRARXRBRXRGATRRORC | |
| SCHEMBL31430803 | 0.78 | RXRA (0.40) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL27378131 | 0.78 | RXRA (0.39) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL30797598 | 0.78 | RXRA (0.39) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL31105893 | 0.78 | LCK (0.41) | RXRARXRBRXRGCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024073073-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174647-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | LRRK2, MAP3K20, MAP3K5 | RXRA 4745/4885RXRB 4668/4885RXRG 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.